Francois Brisebois
Stock Analyst at Oppenheimer
(1.09)
# 3,683
Out of 4,937 analysts
88
Total ratings
29.07%
Success rate
-13.23%
Average return
Main Sectors:
Stocks Rated by Francois Brisebois
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SNSE Sensei Biotherapeutics | Maintains: Outperform | $70 → $80 | $7.65 | +945.75% | 2 | Mar 28, 2025 | |
| ABEO Abeona Therapeutics | Initiates: Outperform | $16 | $6.26 | +155.59% | 1 | Mar 5, 2025 | |
| OVID Ovid Therapeutics | Upgrades: Outperform | $4 | $0.51 | +676.85% | 1 | Jan 29, 2025 | |
| TARS Tarsus Pharmaceuticals | Maintains: Outperform | $65 → $72 | $47.85 | +50.47% | 7 | Jan 22, 2025 | |
| HRMY Harmony Biosciences Holdings | Maintains: Outperform | $59 → $61 | $34.21 | +78.31% | 6 | Jan 13, 2025 | |
| MNMD Mind Medicine (MindMed) | Reiterates: Outperform | $20 | $9.85 | +103.05% | 4 | Dec 17, 2024 | |
| TRDA Entrada Therapeutics | Maintains: Outperform | $25 → $28 | $5.17 | +441.59% | 2 | Nov 6, 2024 | |
| AVDL Avadel Pharmaceuticals | Maintains: Outperform | $29 → $30 | $12.74 | +135.48% | 8 | Oct 31, 2024 | |
| PRAX Praxis Precision Medicines | Maintains: Outperform | $143 → $163 | $45.95 | +254.73% | 4 | Oct 31, 2024 | |
| DYN Dyne Therapeutics | Reiterates: Outperform | $55 | $11.17 | +392.39% | 5 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $15 | $7.42 | +102.16% | 2 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $6 | $4.68 | +28.21% | 5 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $11 | $2.50 | +340.00% | 6 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $17.02 | -17.74% | 2 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $15 | $3.90 | +284.62% | 2 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $15 | $2.65 | +467.11% | 4 | Jun 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $2.29 | +991.70% | 1 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $55 → $65 | $14.17 | +358.72% | 5 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 | $5.26 | +90.11% | 2 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $5 | $1.87 | +167.38% | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $152 | $7.45 | +1,940.27% | 2 | Aug 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $63 → $36 | $18.80 | +91.49% | 4 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $100 → $60 | $0.23 | +25,762.07% | 3 | Apr 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7,200 → $5,400 | $2.91 | +185,467.01% | 2 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $11 | $2.48 | +343.55% | 2 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $18 | $2.66 | +576.69% | 1 | Jul 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $4.39 | +1,038.95% | 1 | Oct 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $3,240 | $1.45 | +223,348.28% | 1 | Feb 4, 2020 |
Sensei Biotherapeutics
Mar 28, 2025
Maintains: Outperform
Price Target: $70 → $80
Current: $7.65
Upside: +945.75%
Abeona Therapeutics
Mar 5, 2025
Initiates: Outperform
Price Target: $16
Current: $6.26
Upside: +155.59%
Ovid Therapeutics
Jan 29, 2025
Upgrades: Outperform
Price Target: $4
Current: $0.51
Upside: +676.85%
Tarsus Pharmaceuticals
Jan 22, 2025
Maintains: Outperform
Price Target: $65 → $72
Current: $47.85
Upside: +50.47%
Harmony Biosciences Holdings
Jan 13, 2025
Maintains: Outperform
Price Target: $59 → $61
Current: $34.21
Upside: +78.31%
Mind Medicine (MindMed)
Dec 17, 2024
Reiterates: Outperform
Price Target: $20
Current: $9.85
Upside: +103.05%
Entrada Therapeutics
Nov 6, 2024
Maintains: Outperform
Price Target: $25 → $28
Current: $5.17
Upside: +441.59%
Avadel Pharmaceuticals
Oct 31, 2024
Maintains: Outperform
Price Target: $29 → $30
Current: $12.74
Upside: +135.48%
Praxis Precision Medicines
Oct 31, 2024
Maintains: Outperform
Price Target: $143 → $163
Current: $45.95
Upside: +254.73%
Dyne Therapeutics
Sep 3, 2024
Reiterates: Outperform
Price Target: $55
Current: $11.17
Upside: +392.39%
Aug 19, 2024
Reiterates: Outperform
Price Target: $15
Current: $7.42
Upside: +102.16%
Aug 16, 2024
Reiterates: Outperform
Price Target: $6
Current: $4.68
Upside: +28.21%
Aug 15, 2024
Reiterates: Outperform
Price Target: $11
Current: $2.50
Upside: +340.00%
Aug 14, 2024
Reiterates: Outperform
Price Target: $14
Current: $17.02
Upside: -17.74%
Aug 9, 2024
Maintains: Outperform
Price Target: $13 → $15
Current: $3.90
Upside: +284.62%
Jun 26, 2024
Maintains: Outperform
Price Target: $11 → $15
Current: $2.65
Upside: +467.11%
Jun 25, 2024
Initiates: Outperform
Price Target: $25
Current: $2.29
Upside: +991.70%
Jun 13, 2024
Maintains: Outperform
Price Target: $55 → $65
Current: $14.17
Upside: +358.72%
May 6, 2024
Reiterates: Outperform
Price Target: $10
Current: $5.26
Upside: +90.11%
Apr 1, 2024
Reiterates: Outperform
Price Target: $5
Current: $1.87
Upside: +167.38%
Aug 30, 2023
Reiterates: Outperform
Price Target: $152
Current: $7.45
Upside: +1,940.27%
Aug 17, 2023
Maintains: Outperform
Price Target: $63 → $36
Current: $18.80
Upside: +91.49%
Apr 3, 2023
Maintains: Outperform
Price Target: $100 → $60
Current: $0.23
Upside: +25,762.07%
Feb 6, 2023
Maintains: Outperform
Price Target: $7,200 → $5,400
Current: $2.91
Upside: +185,467.01%
Aug 29, 2022
Maintains: Outperform
Price Target: $17 → $11
Current: $2.48
Upside: +343.55%
Jul 18, 2022
Assumes: Outperform
Price Target: $18
Current: $2.66
Upside: +576.69%
Oct 29, 2021
Initiates: Outperform
Price Target: $50
Current: $4.39
Upside: +1,038.95%
Feb 4, 2020
Initiates: Buy
Price Target: $3,240
Current: $1.45
Upside: +223,348.28%